The Board of Suven Pharmaceuticals at its meeting held on 30 May 2024 has approved the proposed equity investment of 26% in the SPV (under incorporation) to be engaged in solar power generation for the purpose of captive consumption of the company`s plant operations.Powered by Capital Market - Live News

Net profit of Suven Pharmaceuticals declined 56.95% to Rs 53.37 crore in the quarter ended March 2024 as against Rs 123.97 crore during the previous quarter ended March 2023. Sales declined 31.52% to Rs 252.93 crore in the quarter ended March 2024 as against Rs 369.36 crore during the previous quarter ended March 2023.For the full year,net profit declined 26.99% to Rs 300.28 crore in the year ended March 2024 as against Rs 411.29 crore during the previous year ended March 2023. Sales declined 21.56% to Rs 1051.35 crore in the year ended March 2024 as against Rs 1340.33 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales252.93369.36 -32 1051.351340.33 -22 OPM %29.0046.53 -38.6042.84 - PBDT88.10178.23 -51 460.27607.72 -24 PBT70.85166.21 -57 405.67559.73 -28 NP53.37123.97 -57 300.28411.29 -27 Powered by Capital Market - Live News

Suven Pharmaceuticals has postponed the meeting of the Board of Directors which was scheduled to be held on 27 May 2024. The meeting will now be held on 30 May 2024.Powered by Capital Market - Live News

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27 May 2024Powered by Capital Market - Live News

Suven Pharmaceuticals announced that CRISIL has assigned the rating `CRISIL A+/ Watch Positive (placed on rating watch with positive implications) / CRISIL A1+ (reaffirmed) for bank facilities of the company. Powered by Capital Market - Live News